Background/Introduction Enhanced Supportive Care (ESC) manages challenging symptoms resulting from an individual’s cancer or their cancer treatment through early multidisciplinary care1. The population served and model of service provision in ESC varies between cancer centres. In 2023, Cancer Enhanced Supportive Care (CESC) was introduced at the Bristol Haematology and Oncology Centre serving a population of almost one million (Bristol, North Somerset and South Gloucestershire). Patients with incurable Upper Gastrointestinal and Hepato-Pancreato-Biliary cancers having systemic anti-cancer therapy (SACT) are eligible. Weekly virtual multi-disciplinary team (MDT) meetings highlight patients in need of geriatrician input, using patients’ IPOS score (Integrated Palliative Care Outcome Score), AKPS (Australian Karnofsky Performance Scale), and Clinical Frailty Score (CFS).

Methods Onco-geriatricians provide advice at the MDT and follow-up medically complex or frail patients (telephone or face-to-face). Follow-up clinics rely on the Comprehensive Geriatric Assessment (CGA) to optimise patients’ quality of life (QoL). The CGA has been shown to improve patient outcomes (length of stay, readmission rate, mortality) in medical and surgical specialties and current European wide work on the role geriatricians in oncology is underway(2).

Results During the first four-months, 43 patients, with a median age of 65 years, have been formally discussed with a mean frailty score (CFS) of four (ie vulnerable), (range: 2–9). The Onco-geriatric team have provided input across the following main themes: medical complexity (eg. anaemia and anticoagulation decision making); chronic disease management (eg. diabetes); deprescribing; advanced care planning (in regards to frailty) and input into psycho-social complexity. Patient and health professional feedback has been overwhelmingly positive following geriatric-oncology input.

Conclusions Onco-geriatricians play a vital role in the multidisciplinary care of patients with incurable cancer, alongside disease-targeted treatment. More work is needed to quantify the impact on QoL and any associated cost savings through deprescribing and admission avoidance.